Indaptus Therapeutics (INDP) Competitors $0.59 -0.06 (-9.23%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.60 +0.01 (+1.19%) As of 03/28/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INDP vs. BLUE, FGEN, ALXO, CVKD, OSTX, IRD, TPST, ESLA, RVPH, and XCURShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include bluebird bio (BLUE), FibroGen (FGEN), ALX Oncology (ALXO), Cadrenal Therapeutics (CVKD), OS Therapies (OSTX), Opus Genetics (IRD), Tempest Therapeutics (TPST), Estrella Immunopharma (ESLA), Reviva Pharmaceuticals (RVPH), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. bluebird bio FibroGen ALX Oncology Cadrenal Therapeutics OS Therapies Opus Genetics Tempest Therapeutics Estrella Immunopharma Reviva Pharmaceuticals Exicure Indaptus Therapeutics (NASDAQ:INDP) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation. Which has better earnings and valuation, INDP or BLUE? Indaptus Therapeutics has higher earnings, but lower revenue than bluebird bio. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.42M-$1.62-0.36bluebird bio$53.12M0.75-$211.91M-$45.54-0.09 Do insiders and institutionals hold more shares of INDP or BLUE? 7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 29.5% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 1.4% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer INDP or BLUE? bluebird bio received 1027 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 86.67% of users gave Indaptus Therapeutics an outperform vote while only 70.65% of users gave bluebird bio an outperform vote. CompanyUnderperformOutperformIndaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33%bluebird bioOutperform Votes104070.65% Underperform Votes43229.35% Does the media refer more to INDP or BLUE? In the previous week, bluebird bio had 6 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 8 mentions for bluebird bio and 2 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.94 beat bluebird bio's score of 0.25 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indaptus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive bluebird bio 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate INDP or BLUE? Indaptus Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 1,340.68%. bluebird bio has a consensus price target of $51.00, suggesting a potential upside of 1,150.00%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Indaptus Therapeutics is more favorable than bluebird bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00bluebird bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more volatility and risk, INDP or BLUE? Indaptus Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Is INDP or BLUE more profitable? Indaptus Therapeutics has a net margin of 0.00% compared to bluebird bio's net margin of -565.74%. Indaptus Therapeutics' return on equity of -177.27% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -177.27% -141.06% bluebird bio -565.74%-322.46%-53.17% SummaryIndaptus Therapeutics beats bluebird bio on 10 of the 16 factors compared between the two stocks. Remove Ads Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.51M$6.90B$5.63B$7.84BDividend YieldN/A2.76%5.33%4.01%P/E Ratio-0.357.2623.5518.73Price / SalesN/A218.61388.1990.75Price / CashN/A65.6738.1734.64Price / Book0.416.386.894.23Net Income-$15.42M$142.34M$3.20B$247.47M7 Day Performance-18.09%-5.15%-3.06%-2.29%1 Month Performance-29.68%-7.55%1.51%-5.81%1 Year Performance-73.66%-11.06%9.37%-0.96% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics3.7557 of 5 stars$0.59-9.2%$8.50+1,340.7%-73.7%$8.51MN/A-0.356BLUEbluebird bio2.9754 of 5 stars$3.92+0.5%$51.00+1,201.0%-84.1%$37.92M$53.12M-0.10520Analyst ForecastNews CoverageFGENFibroGen4.5483 of 5 stars$0.37+17.1%$10.00+2,610.0%-86.6%$37.24M$29.62M-0.30570Analyst ForecastNews CoveragePositive NewsGap UpALXOALX Oncology3.8595 of 5 stars$0.69-2.4%$4.14+499.7%-94.1%$36.85MN/A-0.2340CVKDCadrenal Therapeutics2.5748 of 5 stars$19.50+0.7%$32.00+64.1%N/A$36.66MN/A-2.924Short Interest ↑OSTXOS Therapies2.3792 of 5 stars$1.68-2.9%$17.50+941.7%N/A$36.57MN/A0.00N/AIRDOpus Genetics2.3282 of 5 stars$1.15-8.7%$8.00+595.7%N/A$36.30M$8.38M-1.0614Upcoming EarningsHigh Trading VolumeTPSTTempest Therapeutics2.748 of 5 stars$0.83+0.4%$26.00+3,051.5%-80.3%$36.01MN/A-0.5420Earnings ReportUpcoming EarningsAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownESLAEstrella Immunopharma2.4406 of 5 stars$0.99-2.0%$16.00+1,516.5%-23.5%$35.81MN/A-3.81N/APositive NewsRVPHReviva Pharmaceuticals4.2151 of 5 stars$1.07+2.9%$11.40+965.4%-73.3%$35.78MN/A-0.965Short Interest ↓News CoverageXCURExicure1.2519 of 5 stars$13.57-3.4%N/A+2,225.9%$35.36M$500,000.00-6.5650Short Interest ↑News Coverage Remove Ads Related Companies and Tools Related Companies BLUE Alternatives FGEN Alternatives ALXO Alternatives CVKD Alternatives OSTX Alternatives IRD Alternatives TPST Alternatives ESLA Alternatives RVPH Alternatives XCUR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INDP Stock Free INDP Stock Alerts